D. Martinez

The effects of ibudilast, a glial activation inhibitor, on opioid withdrawal symptoms in opioid‐dependent volunteers

Kirk W. Johnson, M. Pavlicova, S. Vosburg, 2016, Addiction biology.

A randomized, double‐blind, placebo‐controlled study of the kappa opioid receptor antagonist, CERC‐501, in a human laboratory model of smoking behavior

E. Nunes, S. Walsh, S. Comer, 2020, Addiction biology.

Biomarkers for the Development of New Medications for Cocaine Dependence

S. Amur, F. Moeller, S. Hemby, 2014, Neuropsychopharmacology.

Repetitive transcranial magnetic stimulation for smoking cessation: a pivotal multicenter double‐blind randomized controlled trial

A. Zangen, Xingbao Li, M. George, 2021, World psychiatry : official journal of the World Psychiatric Association.

Binge alcohol use is not associated with alterations in striatal dopamine receptor binding or dopamine release.

Yiyun Huang, J. Ropchan, N. Nabulsi, 2019, Drug and alcohol dependence.

COVID‐19 complications among patients with opioid use disorder: a retrospective cohort study across five major NYC hospital systems

H. Pincus, F. Levin, K. Schultebraucks, 2022, Addiction.

Racial differences in COVID-19 severity associated with history of substance use disorders and overdose: Findings from multi-site electronic health records in New York City

H. Pincus, F. Levin, K. Schultebraucks, 2023, Preventive medicine.

Effects of ibudilast on oxycodone-induced analgesia and subjective effects in opioid-dependent volunteers.

S. Vosburg, P. Saccone, Z. Cooper, 2017, Drug and alcohol dependence.

The impact of preexisting psychiatric disorders and antidepressant use on COVID-19 related outcomes: a multicenter study.

H. Pincus, F. Levin, K. Schultebraucks, 2023, Molecular psychiatry.

The effects of ibudilast, a glial activation inhibitor, on opioid withdrawal symptoms in opioid‐dependent volunteers

M. Pavlicova, S. Vosburg, P. Saccone, 2016, Addiction Biology.